research Recurrence of Alopecia Areata in a Patient Receiving Etanercept Injections
Etanercept may not prevent alopecia areata from coming back.
Search
for
Sort by
Research
30 / 427 resultsresearch Onset of lichen planopilaris during treatment with etanercept
Etanercept may cause lichen planopilaris, so doctors should be cautious.
research Successful etanercept therapy in therapy refractory acrodermatitis continua suppurativa Hallopeau
Etanercept effectively treated a severe skin condition when other treatments failed.
research Alopecia areata in a patient with psoriatic arthritis and C rohn's disease receiving etanercept
Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.
research Psoriatic onychopachydermoperiostitis: improvement with etanercept
Etanercept improved symptoms of a specific type of psoriatic arthritis in a patient who didn't respond to other treatments.
research Acrodermatitis continua resistant to etanercept: Therapeutic challenge and Unfortunate outcome
A man with Acrodermatitis continua did not get better with etanercept treatment, and his condition worsened, suggesting treatment effectiveness may vary by genetics and race.
research Biologic: A Double Edged Sword - A Case of Etanercept Induced Alopecia Areata in a Patient with Psoriasis Vulgaris
Etanercept, a psoriasis treatment, caused hair loss in a patient.
research Ixekizumab shows efficacy and safety in patients who failed biweekly etanercept therapy: Analysis From UNCOVER-2, a phase 3 randomized clinical trial in psoriasis
Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
research Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
JAK inhibitors show promise for treating alopecia areata, but more research is needed.
research Severe cutaneous adverse reactions to drugs
Some drugs can cause rare but potentially deadly skin reactions, and early treatment and avoiding the drug again are key.
research Safety of dermatologic medications in pregnancy and lactation
Some skin medications are safe during pregnancy and breastfeeding, but others can harm the baby and should be avoided.
research Safety of dermatologic medications in pregnancy and lactation
Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.
research Drugs and Hair Loss
Some medications can cause hair loss, but stopping the drug usually leads to recovery within 3 months.
research Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
research Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
research Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database
Some drugs used to treat inflammation may cause hair loss.
research Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series
Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
research Alopecia universalis during treatment with leflunomide and adalimumab - Case report
A patient lost all their hair while on rheumatoid arthritis medication.
research Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review
A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.
research Novel therapies for alopecia areata: The era of rational drug development
New targeted therapies for hair loss from alopecia areata show promise, with personalized treatment expected in the future.
research Innovative Therapeutics in Pediatric Dermatology
New treatments for skin conditions in children include a preferred drug for birthmark reduction, proactive creams for eczema and vitiligo, a safe psoriasis medication, and special tissues and socks for eczema and fungal infections.
research Successful rapid subcutaneous desensitization to anakinra in a case of delayed‐type hypersensitivity reaction
A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.
research Optimal Management of Plaque Psoriasis in Adolescents: Current Perspectives
The document concludes that proper treatment and management of plaque psoriasis in adolescents can improve their quality of life.
research Ottawa, Ontario, Canada, February 13–16, 2013
The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.
research Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events
Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
research British Association of Dermatologists centenary year: standing on the shoulders of giants
The British Association of Dermatologists celebrated 100 years by looking back at important research, including work on hair loss, skin condition impact, psoriasis treatment, and skin cancer rates.
research Current systemic treatment strategies for hidradenitis suppurativa
Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.
research Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.